sporulation and so shield against recurrent disorder. Given that ibezapolstat therapy results in negligible disruption with the intestine microbiome, bacterial manufacture of secondary bile acids proceeds which may contribute to an anti-recurrence influence. Helpful consequences of bile acids incorp